Mangoceuticals, Inc. (MGRX)
| Market Cap | 13.38M |
| Revenue (ttm) | 516,030 |
| Net Income (ttm) | -15.08M |
| Shares Out | 11.25M |
| EPS (ttm) | -3.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,134,684 |
| Open | 2.170 |
| Previous Close | 1.760 |
| Day's Range | 0.980 - 2.280 |
| 52-Week Range | 0.980 - 6.150 |
| Beta | 2.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2025 |
About MGRX
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and acc... [Read more]
Financial Performance
In 2024, Mangoceuticals's revenue was $615,873, a decrease of -15.81% compared to the previous year's $731,493. Losses were -$9.58 million, 3.97% more than in 2023.
Financial StatementsNews
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc.
Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs
Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company...
Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs
Telehealth company Mangoceuticals said on Thursday it has partnered with Eli Lilly and Novo Nordisk to sell the drugmakers' blockbuster weight-loss drugs through its platform.
Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu
Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and we...
ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market
New York, New York, Dallas, Texas, and Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - ArcStone Securities and Investments Corp. ("ArcStone"), a leading cross-border financial services firm, tod...
CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector
Transaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial Acumen In the news release, "ArcSton...
ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector
Transaction Marks ArcStone's Continued Cross-Border M&A Franchise Involving a NASDAQ-Listed Company, Underscoring the Strength of Its Global Platform and Financial Acumen Transaction Adds Executive Be...
Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ: MGRX) (“Mangoceuticals” or “MGRX”), a company focused on developing, marketing, and selling a variety of health and wellness...
CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape
DALLAS, TX / ACCESS Newswire / April 22, 2025 / Mangoceuticals Inc. (NASDAQ:MGRX) is on a mission to rewrite the playbook for men's performance, health, and vitality. Its pursuit comes at a time when ...
Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation
Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men's wellness products and ser...
Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness produc...
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness pro...
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure teleme...
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and we...
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness pro...
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category
MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health a...
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
Dallas, TX Based Men's Health Telemedicine Company Announces Successful Participation in Beijing Exhibit DALLAS, TX / ACCESSWIRE / August 8, 2024 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the...
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a leader in men's health and wellness products including erectile dysfunction (ED),...
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
DALLAS, TX, July 16, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and ...
MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department
DALLAS, TEXAS, July 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
DALLAS, TEXAS, July 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and...
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
Dallas, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and...